Novartis to buy experimental breast cancer drug in up to $3 billion deal

try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Gold prices rebound but head for deep weekly loss as Iran war dents rate cut bets Stocks end lower in choppy session after Netanyahu says Iran can’t enrich uranium Gold slides on bets for higher interest rates for longer amid raging Iran war Ed Yardeni sees risk to his bullish gold target as prices lag expectations 🧠 Upgrade to AI Insights (South Africa Philippines Nigeria) 🧠 Upgrade to AI Insights Novartis to buy experimental breast cancer drug in up to $3 billion deal By Stock Markets Published 03/20/2026, 04:41 AM Updated 03/20/2026, 04:42 AM Novartis to buy experimental breast cancer drug in up to $3 billion deal 0 NOVN 0.46% FRANKFURT, March 20 - Swiss drugmaker Novartis on Friday agreed to buy a breast cancer drug candidate for up to $3 billion from U.S. biotech firm Synnovation Therapeutics, adding a targeted therapy to its pipeline of cancer drugs. The company will pay $2 billion upfront and up to $1 billion that is contingent on further development achievements as part of the deal. The experimental drug, SNV4818, belongs to a class of selective PI3Kα inhibitors, a new approach for the treatment of a type of breast cancer known as HR positive/HER2 negative and potentially other solid tumours. The acquisition adds to a growing pipeline of targeted cancer therapies, including a radioligand therapy candidate, that Novartis is already testing. SNV4818 is currently in early‑stage trials and has shown promising activity against tumors in lab studies, Novartis said. Synnovation’s drug targets only the mutated form of PI3Kα, an enzyme that often malfunctions in breast and other forms of cancer, while sparing the normal version found in healthy cells. And it aims to avoid the side effects seen with existing PI3Kα-inhibiting therapies. "While mutated PI3Kα is a well‑established driver in HR+/HER2‑ breast cancer, there remains a challenge in achieving effective pathway inhibition with a tolerable therapeutic p...